189 related articles for article (PubMed ID: 17272681)
1. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.
Alli E; Yang JM; Ford JM; Hait WN
Mol Pharmacol; 2007 May; 71(5):1233-40. PubMed ID: 17272681
[TBL] [Abstract][Full Text] [Related]
2. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
Alli E; Bash-Babula J; Yang JM; Hait WN
Cancer Res; 2002 Dec; 62(23):6864-9. PubMed ID: 12460900
[TBL] [Abstract][Full Text] [Related]
3. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.
Wang S; Akhtar J; Wang Z
Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168
[TBL] [Abstract][Full Text] [Related]
4. Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.
Shen F; Long D; Yu T; Chen X; Liao Y; Wu Y; Lin X
Oncol Rep; 2017 Apr; 37(4):2481-2489. PubMed ID: 28259950
[TBL] [Abstract][Full Text] [Related]
5. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
[TBL] [Abstract][Full Text] [Related]
6. Stathmin/Op18 is a novel mediator of vinblastine activity.
Devred F; Tsvetkov PO; Barbier P; Allegro D; Horwitz SB; Makarov AA; Peyrot V
FEBS Lett; 2008 Jul; 582(17):2484-8. PubMed ID: 18588888
[TBL] [Abstract][Full Text] [Related]
7. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
[TBL] [Abstract][Full Text] [Related]
8. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534
[TBL] [Abstract][Full Text] [Related]
9. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
[TBL] [Abstract][Full Text] [Related]
10. Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.
Feng W; Xiaoyan X; Xuan Y; Xiangke L; Zichang Y; Ran Z; Liuxing W; Qingxia F
Cancer Gene Ther; 2015 Apr; 22(3):115-21. PubMed ID: 25572118
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells.
Luker KE; Pica CM; Schreiber RD; Piwnica-Worms D
Cancer Res; 2001 Sep; 61(17):6540-7. PubMed ID: 11522652
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Zhao W; Song Y; Xu B; Zhan Q
Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
[TBL] [Abstract][Full Text] [Related]
13. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.
Lee EA; Keutmann MK; Dowling ML; Harris E; Chan G; Kao GD
Mol Cancer Ther; 2004 Jun; 3(6):661-9. PubMed ID: 15210851
[TBL] [Abstract][Full Text] [Related]
15. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
[TBL] [Abstract][Full Text] [Related]
16. Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel.
Zhu HW; Jiang D; Xie ZY; Zhou MH; Sun DY; Zhao YG
Genet Mol Res; 2015 Dec; 14(4):18695-702. PubMed ID: 26782519
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.
Aoyama M; MacIsaac D; Bukowski RM; Ganapathi MK
Clin Cancer Res; 1998 Apr; 4(4):1039-45. PubMed ID: 9563900
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.
Long M; Yin G; Liu L; Lin F; Wang X; Ren J; Wei J; Dong K; Zhang H
Cancer Gene Ther; 2012 Apr; 19(4):271-81. PubMed ID: 22281755
[TBL] [Abstract][Full Text] [Related]
19. Bistratene A induces a microtubule-dependent block in cytokinesis and altered stathmin expression in HL60 cells.
Johnson WE; Watters DJ; Suniara RK; Brown G; Bunce CM
Biochem Biophys Res Commun; 1999 Jun; 260(1):80-8. PubMed ID: 10381347
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
